Pictet Asset Management Holding SA Sells 27,156 Shares of Becton, Dickinson and Company $BDX

Pictet Asset Management Holding SA cut its stake in Becton, Dickinson and Company (NYSE:BDX) by 17.5% in the 1st quarter, Holdings Channel.com reports. The fund owned 128,156 shares of the medical instruments supplier’s stock after selling 27,156 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Becton, Dickinson and Company were worth $20,150,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of BDX. Brighton Jones LLC increased its holdings in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the period. Empowered Funds LLC lifted its holdings in shares of Becton, Dickinson and Company by 20.4% during the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after acquiring an additional 1,354 shares during the period. United Bank boosted its position in shares of Becton, Dickinson and Company by 23.9% during the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after acquiring an additional 993 shares in the last quarter. Marshall Wace LLP boosted its position in shares of Becton, Dickinson and Company by 365.1% during the 2nd quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after acquiring an additional 25,022 shares in the last quarter. Finally, NewEdge Advisors LLC increased its stake in Becton, Dickinson and Company by 34.7% in the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock valued at $4,048,000 after acquiring an additional 6,058 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Argus cut their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research note on Monday, March 23rd. Wells Fargo & Company lifted their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Weiss Ratings cut Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Evercore upped their price objective on Becton, Dickinson and Company from $180.00 to $190.00 in a research report on Thursday, May 7th. Finally, Stifel Nicolaus decreased their target price on Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus target price of $181.00.

Insider Transactions at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 5,188 shares of company stock valued at $765,120. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 1.0%

NYSE:BDX opened at $152.90 on Thursday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The company has a market cap of $42.13 billion, a PE ratio of 38.71, a P/E/G ratio of 10.71 and a beta of 0.21. The firm’s 50 day simple moving average is $147.91 and its 200 day simple moving average is $169.71.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.Becton, Dickinson and Company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 12.62 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were given a dividend of $1.05 per share. The ex-dividend date was Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio is 106.33%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.